RudaCure asistió the 19th Annual Pain Therapeutics Summit celebrado en San Diego from October 13-14, 2025, gaining insights into the latest changes and investigación trends in the terapéuticos del dolor mercado. At the event, la empresa engaged in active networking with major empresas farmacéuticas including Eli Lilly, Merck, Roche, and J&J, sharing clinical strategies and terapéuticos del dolor mercado trends.
The summit featured presentacións and discussions on the latest investigación into novel tratamiento del dolor targets by numerous groups, with a focus on ensayo clínico design for pain desarrollo de fármacos, emerging pain targets, and advanced therapeutics. RudaCure establecido ongoing networks with empresas showing strong interest in its innovador candidato a fármaco RCI002, creating opportunities to discuss future licenciamiento strategies and tecnología desarrollo directions.
La empresa está preparando to unveil RCI002 el próximo año and will strengthen colaboración with global empresas farmacéuticas to actively pursue mercado global expansion.
